Covid-19 roundup: Vaxart doses first patient in new clinical vaccine study; NIAID launches study to find potential therapies in repurposed drugs
California-based Vaxart has dosed the first patient in a Phase I study of its Covid-19 candidate.
The oral candidate, VXA-CoV2-1, will be tested in up to 48 volunteers ages 18 to 54 years old. The biotech expects to complete enrollment by early November, and receive the first clinical data in the next few weeks. The vaccine could be a one- or two-dose candidate, depending on the outcome of the study.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.